title: Pharmacokinetics of docetaxel in gastric cancer patients with malignant ascites.
abstract: OBJECTIVE
  The purpose of this study was to investigate whether intravenous (i.v.) administration allowed docetaxel to penetrate ascites in gastric cancer patients with peritoneal dissemination.
  
  
  METHODS
  Twelve patients with disseminated gastric carcinoma were enrolled in the study. All patients received docetaxel-containing drug regimens: i.v. administration of 40 mg/m(2) docetaxel in 6 patients, and 60 mg/m(2) in the remainder. Docetaxel concentrations in the plasma and ascites were measured.
  
  
  RESULTS
  Docetaxel was detected in the ascites of 4 patients in the 40 mg/m(2) group and 5 patients in the 60 mg/m(2) group. The highest concentration of docetaxel in plasma was detected at immediately after administration (median: 1,660 ng/mL, 501-2,560 ng/mL), after which it gradually decreased. The highest concentration of docetaxel in ascites was observed at ~7 h after administration and varied among cases (median: 18 ng/mL, 11-52 ng/mL).
  
  
  CONCLUSIONS
  Intravenous administration allows to penetrate ascites in gastric cancer patients with peritoneal dissemination.
authors: Department of Digestive Surgery, Nihon University School of Medicine, 30-1 Ohyaguchi Kamimachi, Itabashi-Ku, Tokyo 173-8610, Japan.
authors: Hidenori
authors: H
authors: Tamegai
authors: Teruo
authors: T
authors: Kaiga
authors: Mitsugu
authors: M
authors: Kochi
authors: Masashi
authors: M
authors: Fujii
authors: Noriaki
authors: N
authors: Kanamori
authors: Yoshiaki
authors: Y
authors: Mihara
authors: Tomoya
authors: T
authors: Funada
authors: Hiroko
authors: H
authors: Shimizu
authors: Daijo
authors: D
authors: Jinno
authors: Tadatoshi
authors: T
authors: Takayama
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001201:Ascites / Q000378:metabolism*; D000077143:Docetaxel; D005260:Female; D005743:Gastrectomy; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000556:secondary; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D043823:Taxoids / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel